4.8 Article

A genetic cell context-dependent role for ZEB1 in lung cancer

Journal

NATURE COMMUNICATIONS
Volume 7, Issue -, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/ncomms12231

Keywords

-

Funding

  1. Mayo Clinic relief award [CA190272RELIEF]
  2. Mayo Center for Individualized Medicine Biomarker Discover programme lung cancer group fund
  3. Mayo Clinic Cancer Center Fraternal Order of Eagles Cancer Research Fund
  4. NCI R21 award [CA184817]
  5. NCI R01 award [CA080127, CA084354]
  6. NCI [K08 CA151661, R21 CA153017]
  7. MD Anderson Cancer Center Physician Scientist Award
  8. NIH [CA125123]
  9. CPRIT grant [RP120713-C2]

Ask authors/readers for more resources

The Zinc-finger E-box-binding Homeobox-1 (ZEB1) is a transcription factor that promotes epithelial-mesenchymal transition (EMT) and acts as an oncogene in KRAS-mutated lung cancer models. Here we report that ZEB1 exerts the opposite effect in EGFR-mutated lung cancer cells, where it suppresses growth by increasing microRNA-200 targets to antagonize ERBB3, a driver of mutant EGFR-dependent cell growth. Among these targets, NOTCH1 represses ERBB3 promoter activity and the expression of ERBB3. Furthermore, we find that EGFR inhibitor treatment, which inhibits the growth of EGFR-mutated cells, induces ZEB1. Despite its growth-inhibiting effect, EGFR inhibitor-induced ZEB1 strongly promotes EMT-dependent resistance to EGFR inhibitors partially through NOTCH1, suggesting a multifunctional role for NOTCH1 in EGFR-mutated cells. These results support a previously unrecognized genetic cell context-dependent role for ZEB1 and suggest that NOTCH1 may be a useful target for treating resistance to EGFR inhibitors, especially EMT-driven resistance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Health Care Sciences & Services

Androgen Mediation-and Antiandrogens Mitigation-of the Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series

Jennifer G. Le-Rademacher, Kendrith Rowland, Pamela J. Atherton, Christopher Dakhil, Zhifu Sun, Angelina Tan, Lucy Schmidt, Phuong L. Nguyen, Carmen Radecki Breitkopf, Mark Pittelkow, Donald Tindall, Smitha Menon, Aminah Jatoi

AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE (2019)

Article Biochemistry & Molecular Biology

Nuclear TAZ activity distinctly associates with subtypes of non-small cell lung cancer

Yuanyuan Wang, Yang Han, Zhongliang Guo, Yanan Yang, Tao Ren

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)

Article Genetics & Heredity

Predict drug sensitivity of cancer cells with pathway activity inference

Xuewei Wang, Zhifu Sun, Michael T. Zimmermann, Andrej Bugrim, Jean-Pierre Kocher

BMC MEDICAL GENOMICS (2019)

Article Oncology

Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

Yong-An Song, Ting Ma, Xue-Yan Zhang, Xiang-Song Cheng, Ayobami-Matthew Olajuyin, Zhi-Fu Sun, Xiao-Ju Zhang

CANCER CELL INTERNATIONAL (2019)

Article Multidisciplinary Sciences

Use of FFPE-derived DNA in next generation sequencing: DNA extraction methods

Samantha J. McDonough, Aditya Bhagwate, Zhifu Sun, Chen Wang, Michael Zschunke, Joshua A. Gorman, Karla J. Kopp, Julie M. Cunningham

PLOS ONE (2019)

Article Infectious Diseases

Protein expression shift and potential diagnostic markers through proteomics profiling of tuberculous pleurisy biopsy tissues

Wei-xia Xuan, Jin-jin Li, Qun-cheng Zhang, Guan-nan Sun, Zhi-wei Xu, Zhi-fu Sun, Xiao-ju Zhang

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)

Article Genetics & Heredity

Novel lincRNA Discovery and Tissue-Specific Gene Expression across 30 Normal Human Tissues

Xianfeng Chen, Zhifu Sun

Summary: This study utilized a novel lncRNA discovery pipeline and RNA-seq data resources to systematically discover novel lincRNAs in 30 major human tissue types, which defined the characteristics of each tissue type and demonstrated their reliability and tissue-specific expression. Tissue-specific genes were identified for each major tissue type, providing insight into each respective tissue's unique function and expanding interpretation of non-coding SNPs from genome-wide association studies.

GENES (2021)

Review Cell Biology

The Mitochondrial Response to DNA Damage

Ziye Rong, Peipei Tu, Peiqi Xu, Yan Sun, Fangfang Yu, Na Tu, Lixia Guo, Yanan Yang

Summary: Mitochondria are essential organelles in eukaryotic cells that provide energy through oxidative phosphorylation. Mitochondrial DNA is prone to damage by DNA damaging agents, which can lead to dysfunction and contribute to various human diseases. Understanding mtDNA repair mechanisms is crucial for developing therapeutic strategies.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Article Biochemistry & Molecular Biology

Exendin-4 may improve type 2 diabetes by modulating the epigenetic modifications of pancreatic histone H3 in STZ-induced diabetic C57BL/6 J mice

Peipei Tu, Bin Huang, Minggang Li, Yaofang Zhang, Shixiang Bao, Na Tu, Yanan Yang, Jingtao Lu

Summary: Type 2 diabetes (T2D) is a complex systemic disease that might benefit from treatment with exendin-4, as shown in this study on C57BL/6 J mice. The study investigated epigenetic alterations in pancreatic tissues of diabetic mice and demonstrated an improvement in T2D progression with exendin-4 treatment through modulation of histone acetylation and methylation patterns. Understanding these epigenetic changes may lead to novel therapeutic approaches for T2D.

JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY (2022)

Review Immunology

A diversified role for γδT cells in vector-borne diseases

Chen Chen, Aibao Chen, Yanan Yang

Summary: Vector-borne diseases pose major health threats globally, and γδT cells play a crucial role in regulating host-pathogen interactions and disease progression.

FRONTIERS IN IMMUNOLOGY (2022)

Article Oncology

Lynch syndrome pre-screening and comprehensive characterization in a multi-center large cohort of Chinese patients with colorectal cancer

Yan Li, Lihong Fan, Jianming Zheng, Xiu Nie, Yu Sun, Qin Feng, Shenyi Lian, Wenqi Bai, Weijing Cai, Yanan Yang, Bo Su, Yanfeng Xi, Dongmei Lin

Summary: This study systematically investigated the pre-screening methods and characterized the genetic and clinical features of Lynch syndrome (LS) colorectal cancers (CRCs) in Asia. The results demonstrated that MMR IHC and MSI testing were effective methods for LS pre-screening and identified previously unreported pathogenic germline variants of MMR genes in LS patients.

CANCER BIOLOGY & MEDICINE (2022)

Article Genetics & Heredity

Performance comparisons of methylation and structural variants from low-input whole-genome methylation sequencing

Zhifu Sun, Saurabh Behati, Panwen Wang, Aditya Bhagwate, Samantha McDonough, Vivian Wang, William Taylor, Julie Cunningham, John Kisiel

Summary: Whole-genome methylation sequencing provides both DNA methylation and structural variant information. However, there is limited data on the reliability of obtaining this information simultaneously from low-input DNA using different library preparation and sequencing protocols. This study compared the performance of three protocols (EM-sequencing, QIA-sequencing, and Swift-sequencing) on CpG methylation measurement, SNV, and CNV detection. Results showed that at low DNA input, EM-sequencing was superior in most metrics except for CNV detection. EM-sequencing captured the highest number of CpGs and true SNVs, making it suitable for detecting methylation, SNVs, and CNVs from low-input DNA in a single sequencing.

EPIGENOMICS (2023)

Article Oncology

Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation

Yung-Hung Luo, Han Liu, Jason A. Wampfler, Henry D. Tazelaar, Yalun Li, Tobias Peikert, Dan Liu, Konstantinos Leventakos, Yuh-Min Chen, Yanan Yang, Shih-Hwa Chiou, Ping Yang

Summary: This study demonstrates that osimertinib as a second or subsequent line of treatment in patients previously treated with EGFR-TKIs without identification of T790M mutation showed a lower risk of death compared to those who received first-line or second-generation TKIs without subsequent osimertinib. Patients with EGFR mutations and PD-L1 expression >= 50% had a higher risk of treatment failure with osimertinib and worse overall survival. These results suggest that osimertinib as a second-line or subsequent treatment may be a potential alternative for patients without identification of T790M, while high PD-L1 expression is associated with poor outcomes in patients receiving osimertinib.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Article Medicine, Research & Experimental

BMI1 maintains the Treg epigenomic landscape to prevent inflammatory bowel disease

Michelle M. Gonzalez, Adebowale O. Bamidele, Phyllis A. Svingen, Mary R. Sagstetter, Thomas C. Smyrk, Joseph M. Gaballa, Feda H. Hamdan, Robyn Laura Kosinsky, Hunter R. Gibbons, Zhifu Sun, Zhenqing Ye, Asha Nair, Guilherme P. Ramos, Manuel B. Braga Neto, Alexander Q. Wixom, Angela J. Mathison, Steven A. Johnsen, Raul Urrutia, William A. Faubion

Summary: Research has shown that BMI1 regulates the inflammatory enhancer network in Treg cells, and its loss leads to systemic inflammation and phenotypic conversion of Treg cells, which is relevant to CD4(+) T cells associated with Crohn's disease.

JOURNAL OF CLINICAL INVESTIGATION (2021)

No Data Available